News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
11 Aug 2022
In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.
Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
11 Aug 2022
Men with PsA derive more benefit from MTX+ETN therapy than women
09 Aug 2022
byStephen Padilla
Combination therapy with methotrexate (MTX) plus etanercept (ETN) results in more improved outcomes in men than in women with psoriatic arthritis (PsA) for minimal disease activity (MDA) and Psoriatic Arthritis Disease Activity Score (PASDAS), a study has shown.
Men with PsA derive more benefit from MTX+ETN therapy than women
09 Aug 2022
Ivabradine SR improves heart function in patients with HFrEF
08 Aug 2022
Once-daily treatment with sustained-release (SR) ivabradine hemisulfate, alongside optimum standard therapy, results in better heart function in patients with chronic heart failure with reduced ejection fraction (HFrEF), reports a study.






